The book's four parts describe the European Agency for the Evaluation of Medicinal Products's (EMEA) approval process. They explain the application procedure, requirements, and how to obtain marketing authorization to make finished medicinal products commercially available in the European market.
Part A deals with the procedures, laws, and material requirements for marketing authorization. Chapters 2 and 3 briefly discuss the essential terms and provisions of the EU's pharmaceutical laws and describe EMEA's organizational structure and responsibilities.
This part also provides a detailed description of the application procedure for marketing authorization. It explains requirements, including data about the quality of drug substances and drug products, and nonclinical and clinical study reports, that should be included in EU CTD modules 1–5. In addition, the section provides regional administrative information for each EU member country; high-level summaries of product quality, safety, and efficacy; and clinical and nonclinical data. The last chapter includes the approval process for granting the marketing authorization in Switzerland, which is not an EU country.
Part C explains how to obtain marketing authorization for special drug products, including blood and blood products, advanced therapy medicinal products, radiopharmaceuticals, orphan drugs, and traditional herbal medicines.
The last part of the book provides helpful information such as a list of Internet resources and application forms.
The editors and authors have taken exceptional care to italicize and highlight the important words, definitions, tables, and paragraphs in each part of the book. This book supplies relevant details about the process for getting EMEA approval for medicinal products and special drug products. It examines EMEA's role in regulating human drug marketing.
This book contains many legal and regulatory references for the European marketing-authorization procedure. It is most useful for readers who wish to gain a deep understanding of the procedural and legal issues involved in submitting medicinal products to the EU and EMEA for approval.
The book is more than 1000 pages long and might be a little intimidating to those who seek quick references when filing for marketing authorization in Europe. The authors have worked diligently, however, to ensure that the book's contents are well presented. On the other hand, the book lacks a short summary of each of its parts. Therefore, readers may have difficulty finding information quickly about the filing process for approval.
Not many references for this subject are available, and this one is written in a simple way that makes it useful to the pharmaceutical industry and to regulators. In brief, the book supplies everything a manufacturer would need to plan a regulatory filing.
Naushad Khan Ghilzai is an associate professor in the Department of Pharmaceutical Sciences, LECOM School of Pharmacy, 1858 W. Grand-view Blvd., Erie, PA 16509, tel. 814.860.5134, fax 814.860.5123, [email protected]